BioSenic S.A. (0R55.L)

0.0148 +0.0002 (+1.37%) At close: 02:11PM BST

BioSenic S.A.

Building H (box 24)
Rue GranbonprE 11
Mont-Saint-Guibert 1435
Belgium
32 493 09 73 66
https://www.biosenic.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Prof. François Rieger	CEO & Chairman	N/A	N/A	1944
Dr. Carole Nicco	Chief Scientific Officer	N/A	N/A	1973
Ms. Alexia Rieger	Chief Investor Relation Officer	N/A	N/A	1996
Ms. Véronique Pomi-Schneiter	Deputy CEO & Exec. Director	N/A	N/A	1965
Dr. Lieven Huysse M.D.	Chief Medical Officer	N/A	N/A	1969

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

Corporate governance

BioSenic S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.